Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Recommendation of “Moderate Buy” by Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH) has earned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $22.1667.

Several research analysts have issued reports on the stock. Weiss Ratings upgraded shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. BTIG Research reiterated a “buy” rating and set a $17.00 price objective on shares of Delcath Systems in a research report on Monday, July 13th. Finally, Zacks Research raised Delcath Systems from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th.

Delcath Systems Trading Up 0.3%

NASDAQ:DCTH opened at $11.58 on Thursday. The company has a 50-day moving average of $12.02 and a 200-day moving average of $10.73. The firm has a market cap of $399.74 million, a price-to-earnings ratio of 1,158.00 and a beta of 0.49. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $13.74.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Thursday, May 7th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. The business had revenue of $24.99 million for the quarter, compared to the consensus estimate of $23.51 million. On average, research analysts forecast that Delcath Systems will post -0.88 earnings per share for the current year.

Institutional Investors Weigh In On Delcath Systems

A number of large investors have recently made changes to their positions in the company. California State Teachers Retirement System purchased a new position in Delcath Systems during the 2nd quarter worth approximately $26,000. Russell Investments Group Ltd. purchased a new stake in shares of Delcath Systems in the third quarter valued at $29,000. Tower Research Capital LLC TRC acquired a new stake in shares of Delcath Systems in the second quarter worth $40,000. Legal & General Group Plc acquired a new stake in shares of Delcath Systems in the second quarter worth $46,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Delcath Systems during the second quarter valued at $151,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.